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Type 1 ST-segment elevation is diagnostic of Brugada syndrome and its presence may be associated
with a high risk of arrhythmic events. However, similar changes on electrocardiogram (ECG) are
observed in various normal and abnormal conditions. A type 1 ECG can also be unmasked by
administration of sodium channel blockers in equivocal or suspected cases of Brugada syndrome,
and this drug challenge test is frequently used in the diagnosis of symptomatic patients showing non-
type 1 ECG patterns. The presence of a transient spontaneous type 1 ECG rather than a drug-induced
type I ECG is an important sign for risk prediction of arrhythmia events, even in asymptomatic patients.
In asymptomatic individuals, multiple and repeated ECG recordings rather than drug testing are
recommended for detecting the transient appearance of a spontaneous type 1 ECG, which may indicate
the future development of arrhythmic events. There is little doubt that ECG interpretation, including
diagnostic criteria and differential diagnosis, constitutes the hallmark of Brugada syndrome.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.Contents1. Diagnostic ECG criteria for Brugada syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
1.1. Consensus reports from the United States and Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
1.2. Automatic criteria for computerized diagnosis in Japan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
1.3. Other ECG characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2. Multiple factors inﬂuencing Brugada-type ECG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3. Differential diagnosis of Brugada-type ECG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4. Manifestations of Brugada-type ECG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.1. Pharmacologic provocation test. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.2. Other recording procedures and provocation tests. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614.2.1. Recording at the higher lead positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.2.2. Exercise testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.2.3. Glucose tolerance test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.2.4. Full-stomach test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.2.5. Multiple and repeated recording over multiple days and within a single day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625. Clinical implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Conﬂict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63rt Rhythm Society. Published by E
Yokohama Minami Kyosai
ohama, Kanagawa 236-0037,
izaki).1. Diagnostic ECG criteria for Brugada syndrome
1.1. Consensus reports from the United States and Europe
Brugada syndrome is characterized by unique changes on
electrocardiogram (ECG) and carries a high risk for sudden cardiaclsevier B.V. All rights reserved.
M. Nishizaki et al. / Journal of Arrhythmia 29 (2013) 56–64 57death (SCD) due to ventricular ﬁbrillation (VF) in patients without
major structural heart disease. [1–8] Consensus reports from the
subgroup of the Heart Rhythm Society and European Heart
Rhythm Association have proposed the diagnostic ECG criteria
for Brugada syndrome. [9,10] According to these consensus
reports, there are 3 ECG patterns: type 1, type 2, and type 3
(Fig. 1A). Type 1 is deﬁned as a coved-type ST-segment elevation
Z2 mm (0.2 mV) followed by a negative T wave. Type 2 ST-
segment elevation has a saddleback appearance with a high-
takeoff ST-segment elevation of Z2 mm, a trough displaying
Z1 mm ST elevation, and then either a positive or biphasic T
wave. Type 3 has either a saddleback appearance or a coved-type
ST-segment elevation of o1 mm (Fig. 1B). Type 2 and type 3 ECG
are not diagnostic of Brugada syndrome.
A type 1 ECG pattern is regarded as a diagnostic sign for Brugada
syndrome, and a ﬁnal diagnosis can be made when at least 1 of the
following conditions are associated with ECG changes: documented
VF and/or polymorphic ventricular tachycardia (VT), a family
history of SCD at o45 years of age, type 1 ECG in family members,
induction of VT/VF by programmed ventricular stimulation (PVS),
and syncope or nocturnal agonal respiration. The presence of a
drug-induced type 1 ECG following sodium channel blocker admin-
istration is also considered a diagnostic sign for Brugada syndrome
in the consensus report [10].Fig. 1. (A) Three electrocardiogram (ECG) repolarization patterns in Brugada syndrome:
permission). (B) Three ECG patterns in the precordial leads in Brugada syndrome (adaOn the other hand, according to the recommendations for
implantable cardioverter-deﬁbrillator (ICD) implantation in the
Japanese Circulation Society guideline, type 1 ECG recordings at a
superior lead position in addition to drug provocation testing are
also considered a diagnostic sign [11].1.2. Automatic criteria for computerized diagnosis in Japan
Although 2 ST-segment elevation waveforms have been recog-
nized in Brugada syndrome cases [3,4], the consensus report
divided these waveforms into type 1, type 2, and type 3 [9,10].
While the initial report indicated persistent ST-segment elevation
as a characteristic ECG ﬁnding of Brugada syndrome [1], the
ﬂuctuating nature of ST elevation over time was recognized as a
general feature of this syndrome [3,4]. The development of a
spontaneous type 1 ECG pattern was regarded as an important
clinical sign for predicting the cardiac events and prognosis of
patients with Brugada syndrome [7,8,12], although other reports
did not support this notion [13,14]. These ﬁndings may indicate
that the detection of a type 1 ECG as a diagnostic sign proposed by
the consensus report may not always be applicable and can
be missed in certain cases due to the inconsistent appearance
of a speciﬁc ST-segment elevation pattern. Another diagnosticST–T abnormalities in leads V1–V3 (adapted from the consensus report [9,10] with
pted from the consensus report [9] with permission).
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Brugada syndrome with respect to the types of ST-segment
elevation, since the long-term prognosis of Brugada syndrome
patients in the non-type 1 group was similar to that of the type 1
group [14]. There was a missing form of ST-segment elevation
among the 3 types included in the consensus report: a coved-type
ST-segment elevation with J wave amplitude between 0.1 mVr
and o0.2 mV. Therefore, the Brugada-type ECGs based on com-
puterized diagnosis were divided into three types, depending on
the ST-segment elevation morphology and J wave amplitude.
Type 1 has a coved-type ST-segment elevation with a J wave
amplitude of Z0.2 mV, which was equivalent to type 1 in the
consensus report. [9,10] Type 2/3 has saddleback-type ST-seg-
ment elevation with a J wave amplitude of Z0.2 mV. Type S,
an abbreviation of ‘‘suggestive,’’ was deﬁned as a coved-type
ST-segment elevation with a J wave amplitude between 0.1 mVr
and o0.2 mV (Fig. 2A). Type S was included because of the
occasional association of an increased risk of VF or SCD in
Japanese Brugada syndrome cases [5,14–19].
The automatic diagnostic criteria for each ECG type were estab-
lished by the J-point amplitude, ST-segment elevation with its
characteristic amplitude and conﬁguration, and the T-wave mor-
phology in leads V1–V3. The automatic diagnostic criteria for type 1,
type 2/3, and type S Brugada-type ECGs are summarized in Fig. 2B.
ECG data from the annual health examinations of 36,674
workers and 155,999 school-age children were used to evaluateFig. 2. (A) Three types of ECG records automatically diagnosed by the proposed criter
and type S Brugada-type ECGs [20] with permission.the diagnostic accuracy of the proposed criteria. The proposed
criteria demonstrated a reasonable accuracy (type 1: 91.9%, type
2/3: 86.2%, and type S: 76.2%) for diagnosing Brugada-type ECG in
comparison to macroscopic diagnosis by experienced observers.
Moreover, the automatic criteria had a comparable detection rate
(0.6% in adults and 0.16% in children) between Brugada-type ECGs
and macroscopic inspection in the health screening examinations.
The numbers detected by the automatic criteria for types 1, 2/3,
and S were 20 (0.05%), 161 (0.44%), and 40 cases (0.11%),
respectively, of the total cases [20]. Therefore, non-type 1 (types
2/3 and S) ECG patterns were detected in 0.55% of adults, most of
whom were usually asymptomatic.
Consequently, the automatic diagnostic criteria for type 1, type
2/3, and type S ECG patterns were established to detect Brugada-
type ECG patterns in leads V1–V3. The criteria could differentiate
between Brugada-type ECGs and those showing right bundle
branch block (RBBB). The three criteria had a comparable detec-
tion rate between Brugada-type ECGs and macroscopic inspection
by experienced observers in the health screening examinations of
adults and school-age children [20].1.3. Other ECG characteristics
Apart from typical ST-segment elevation, depolarization
abnormalities such as the prolongation of the P wave duration,ia [20] with permission. (B) The automatic diagnostic criteria of type 1, type 2/3,
Fig. 3. Multiple factors inﬂuence the ST–T wave in Brugada syndrome [54] with permission. A type 1 ECG (coved-type ST-segment elevation) develops from a non-type
1 ECG due to various factors, including antiarrhythmic drugs.
Table 1
Differential diagnosis representing ST-segment elevation in the right precordial
leads. (Adapted from the report of consensus report [9]).
(1) Right or left bundle branch block, left ventricular hypertrophy
(2) Acute myocardial ischemia or infarction
(3) Acute myocarditis or pericarditis
(4) Right ventricular ischemia or infarction
(5) Dissecting aortic aneurysm
(6) Acute pulmonary thromboemboli
(7) Variant angina pectoris
(8) Various central and autonomic nervous system abnormalities
(9) Heterocyclic antidepressant overdose
(10) Duchenne muscular dystrophy
(11) Friedreich’s ataxia
(12) Thiamine deﬁciency
(13) Hypercalcemia
(14) Hyperkalemia
(15) Hypothermia
(16) Mediastinal tumor or hemopericardium compressing RVOT
(17) Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(18) Long-QT syndrome (type 3)
Other conditions that can lead to ST-segment elevation in the right
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the PR interval is thought to reﬂect HV conduction delay [9,10].
These longer conduction intervals are more likely to be detected
in patients with a sodium channel protein type 5 subunit alpha
(SCN5A) mutation [21]. The QT interval is prolonged more
frequently in the right precordial leads than in the left precordial
leads. However, a shorter-than-normal QT interval is less fre-
quently recognized in patients displaying ST-segment elevation in
leads V1–V3, which is associated with mutations in genes encod-
ing the cardiac L-type calcium channel [22]. Width prolongation
in the terminal portion of the right precordial S wave reveals an
arrhythmogenic substrate associated with lethal ventricular
arrhythmias [23]. Recently, it has been reported that the PQ
interval (Z170 ms) and a negative T wave (o105 mV) in lead
V1 based on computer-processed analysis are independently
associated with life-threatening events [24]. Moreover, multiple
spikes within the QRS complex (fragmented QRS) in leads V1–V3
are known to be a marker of conduction abnormality and a
reliable predictor of prognosis [12,25].precordial leads
(1) Early repolarization syndrome
(2) Other normal variants (particularly in men)2. Multiple factors inﬂuencing Brugada-type ECG
The ECG pattern is dynamic, variable, and often concealed.
Multiple factors have been shown to inﬂuence ST-segment
elevation in Brugada syndrome patients and suspected cases.
These factors include changes in heart rate, body temperature,
autonomic imbalance, glucose-induced insulin secretion, sodium
channel blockers, and so others [3,4,10,26–36] (Fig. 3). Among
these factors, sodium channel blockers have the most critical
inﬂuence on patients with Brugada syndrome and related condi-
tions because of their actions of unmasking ST elevation and
inducing serious arrhythmic events as unexpected or side effects
[3,4,10,26,27]. Other classes and types of drugs are also known to
affect ST-segment elevation and arrhythmia development in
manifest and latent Brugada syndrome patients. Recently, drugs
that should be avoided by Brugada syndrome patients have been
listed on a website (/http://www.brugadadrugs.orgS) due to the
occasional and unexpected development of Brugada-type ST
elevation and ventricular tachyarrhythmias [37]. Drugs used in
Brugada syndrome patients and suspected cases are categorized
into four groups: (1) drugs to be avoided; (2) drugs to be
preferably avoided; (3) antiarrhythmic drugs; and (4) diagnosticdrugs. Sodium channel blockers are recommended diagnostic
drugs for Brugada syndrome. Pilsicainide exhibits the properties
of a pure sodium channel blocker and has been recommended for
the diagnosis of suspected cases in Japan. On the other hand,
quinidine is classiﬁed as a sodium channel blocker and has
been shown to be effective in suppressing ST-segment elevation
and preventing VTs. [38,39] The preventive effects of quinidine
are supposedly exerted through its action on the speciﬁc Kþ
current, Ito.
The morphology and degree of ST-segment elevation may also
be inﬂuenced by the position of the recording electrodes. A higher
right precordial lead placement than the conventional position at
V1V3 can also be used to unmask the Brugada-type ECG in
subjects without typical ECG changes or unequivocal signs
[40–42]. Demonstration and unmasking of the type 1 ECG pattern
at the higher lead positions also have diagnostic value for Brugada
syndrome, similar to its appearance at the conventional lead
position of V1V3 [40–42].
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ECG changes that are similar to those of Brugada syndrome are
observed in various normal and abnormal conditions, including
early repolarization in apparently healthy individuals and young
athletes as well as cases of left ventricular hypertrophy, acute
myocardial infarction, pericarditis, variant angina pectoris,
arrhythmogenic right ventricular cardiomyopathy (ARVC), pul-
monary embolism, and hyperkalemia [3,4,9,10,43–45]. Differen-
tial diagnoses for patients showing ST-segment elevation in the
right precordial leads are shown in Table 1.
In particular, differential diagnosis between Brugada syn-
drome and ARVC on ECG may be difﬁcult. Common ECG features
of ARVC represent depolarization/repolarization abnormalitiesI
III
II
aVR
aVL
aVF
Fig. 4. (A) Twelve-lead ECG in a patient with arrhythmogenic right ventricular cardiomy
and an inverted T wave in the right precordial leads due to depolarization/repolarization
observed in lead V1. (B) Twelve-lead ECG in a patient with variant angina. The ECG
a reciprocal ST–T wave change is recognized in leads I, aVL, V5, and V6.such as an epsilon wave, prolongation of the QRS interval, late
potential, and an inverted T wave in the right precordial leads
[9,10] (Fig. 4A). Moreover, monomorphic VT with left bundle
branch block morphology facilitated occasionally by catechola-
mines and exercise is observed in patients with ARVC, and its
mechanism involves scar-related reentry. In contrast, the electro-
genesis of polymorphic ventricular tachycardia degenerating into
VF in Brugada syndrome patients is thought to involve phase-2
reentry [9,10]. ST-segment elevation in the right precordial leads
is often enhanced by vagotonic agents and life-threatening
ventricular arrhythmias frequently occur at rest, after meals, or
during sleep. Unlike ARVC, the level and morphology of ST
elevation spontaneously ﬂuctuate over multiple days and within
a single day, and the typical ECG changes do not exhibit a stableV1
V2
V3
V4
V5
V6
opathy (ARVC). This patient has an epsilon wave, prolongation of the QRS interval,
abnormalities. ST-segment morphology similar to mild coved-type ST elevation is
features represent non-type 1 ST-segment elevation in lead V1–V4. Moreover,
M. Nishizaki et al. / Journal of Arrhythmia 29 (2013) 56–64 61expression pattern. A type 1 ECG is unmasked by administration
of sodium channel blockers in Brugada syndrome patients,
whereas ARVC patients do not exhibit ST–T wave changes related
to repolarization abnormalities during drug challenge testing.
The morphologies of ST-segment elevation in Brugada syn-
drome are also similar to those observed during variant angina
and SCD occurs during sleep in both diseases, which is often due
to polymorphic ventricular tachycardia degenerating into VF
[46,47]. Moreover, the coexistence of both diseases in the same
patients has been observed occasionally. [43–45] ST-segment
elevation in variant angina patients is detected brieﬂy during
spontaneous chest pain or intracoronary injection of acetylcholine
in the precordial and inferior leads, accompanied by reciprocal
ST–T wave changes (Fig. 4B). Furthermore, unlike Brugada syn-
drome, administration of sodium channel blockers does not affect
ST-segment changes in patients with variant angina. On the other
hand, ECG manifestations in Brugada syndrome patients repre-
sent persistent or ﬂuctuating ST-segment elevation in the right
precordial leads from V1 to V3, which is improved during exercise
testing. The reciprocal ST–T wave change is not recognized on
ECG in Brugada syndrome.4. Manifestations of Brugada-type ECG
4.1. Pharmacologic provocation test
The presence of a transient spontaneous type 1 ECG rather
than drug-induced type 1 ECG is an important sign for risk
prediction of arrhythmic events, even in asymptomatic patients
[7–10,12,48]. Therefore, the spontaneous type 1 ECG pattern
appears to represent an important predictive sign for cardiac
events. On the other hand, because the demonstration of a drug-
induced type 1 ECG is sometimes associated with the develop-
ment of arrhythmic events in symptomatic patients, this test
should be applicable to symptomatic patients showing non-type
1 ECG patterns [26–28,49]. In patients with type 2 and 3 ECGs,Fig. 5. ECG from a symptomatic patient after administration of pilsicainide and while r
marked ST-segment elevation and ST-segment morphology from saddleback-type to cov
at the upper intercostal lead position is similar to that noted after pilsicainide administhis test is recommended to clarify the diagnosis, and a change of
the ST–T wave into a type 1 ECG pattern is considered positive
[9,10] (Fig. 5).
Sodium channel blockers such as procainamide, ﬂecainide,
ajimaline, propafenone, and pilsicainide have been used to
unmask the type 1 ECG pattern when it is initially absent [9,10].
In particular, the efﬁcacy of the sodium channel blocker challenge
test using pilsicainide in patients with a Brugada type ECG or
normal ECG has been explored in several studies. In these studies,
adverse effects of pilsicainide administration, including VT/VF,
frequent premature ventricular contractions, marked ST eleva-
tion, or extensive QRS prolongation, occurred in approximately
13% of the study population who did not have a spontaneous type
1 ECG pattern [50–52]. Therefore, the pilsicainide challenge test
should be performed carefully in asymptomatic individuals with a
non-type 1 ECG, with consideration given to both the beneﬁcial
and adverse effects. Blood pressure monitoring and 12-lead ECG
examinations are strongly recommended during drug testing
until the ECG has normalized. Administration of isoproterenol is
effective in successfully suppressing ventricular arrhythmias that
occur during the challenge test.
4.2. Other recording procedures and provocation tests
4.2.1. Recording at the higher lead positions
ECG recording at the upper intercostal lead positions of the
right precordial leads (V1V3) has a high sensitivity of diagnostic
accuracy and is often recommended as a measure for unmasking
Brugada syndrome [9,10,40–42] (Fig. 5). The diagnostic effective-
ness of the method was supported by the result demonstrating
that no healthy subjects displayed a type 1 ECG when the V1V3
leads were displaced upward [40–42]. However, the mechanisms
underlying its diagnostic usefulness have not been explored in
detail. Recording at the upper intercostal lead positions may
produce closer apposition of the right ventricular outﬂow tract
to the lead positions compared with those at the standard lead
positions (the 4th intercostal space).ecording at the upper intercostal lead position. After administration of pilsicainide,
ed-type elevation are observed in lead V2. The ST–T wave change in the recording
tration.
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A type 1 ECG pattern is occasionally unmasked in Brugada
syndrome patients during the recovery phase following exercise
testing (Fig. 6). Augmentation of ST-segment elevation can be
provoked directly by inhibition of the calcium channel current or
a decrease in heart rate as a consequence of decreased adrenergic
tone and a concomitant increase in vagal tone during early
recovery after exercise [9,10,28]. Moreover, it has been reported
that augmentation of ST-segment elevation during recovery from
exercise testing can be a predictor of poor prognosis, particularly
in patients with syncope alone and asymptomatic patients [53].
On the contrary, sympathetic stimulation during exercise may be
related to a decrease in phase 1 amplitude Ito at faster rates,
leading to a decrease in J point and ST-segment elevation and
therefore a decrease in the incidence of ventricular arrhythmias.4.2.3. Glucose tolerance test
Brugada syndrome patients often exhibit augmentation of
ST-segment elevation and a morphologic change in the ST–T wave
after glucose loading during glucose tolerance testing. A type
1 ECG is manifested with increased insulin levels after glucose
loading in some patients with Brugada syndrome [30,31] (Fig. 7).
These changes are mostly reversible with normalization of insulin
level. It is assumed that the glucose-induced insulin level after
glucose loading in Brugada syndrome patients is associated with
augmentation and morphologic changes in ST-segment elevation
[30,31]. Insulin has been shown to cause hyperpolarization of theI
Baseline
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
HR = 80beats/min
During exe
169 be
Fig. 6. Twelve-lead ECG during exercise testing in a symptomatic patient. The ST-segm
manifested during the recovery phase from exercise testing. HR¼heart rate.membrane potential by activation of the Naþ/Kþ pump, which
activates the outward current during the plateau phase. There-
fore, glucose-induced insulin secretion is one of the factors that
contribute to induction or aggravation of ST-segment abnormal-
ities in Brugada syndrome patients.
4.2.4. Full-stomach test
It has been reported that ST–T abnormalities were induced by
consumption of a large meal in Brugada syndrome patients. It was
suggested that a stomach rapidly ﬁlled with a large meal (full-
stomach test) leads to increased vagal tone and causes augmenta-
tion and morphologic changes in ST-segment elevation [32]. This
test may be valuable to reveal the type 1 ECG pattern in Brugada
syndrome. Moreover, characteristic ECG abnormalities observed
after large meals are associated with a history of life-threatening
events in patients with Brugada syndrome.
4.2.5. Multiple and repeated recording over multiple days and
within a single day
The level and morphology of ST elevation in Brugada syn-
drome patients spontaneously ﬂuctuate over time, as shown in
Fig. 8 [36]. Therefore, multiple and repeated ECG recordings
rather than drug testing is recommended for the detection of a
transient spontaneous type 1 ECG pattern, which may predict
the future development of arrhythmic events [34–36]. On the
other hand, Brugada syndrome patients exhibit variations in
ST-segment elevation in association with meals, particularly withrcise Recovery phase
ats/min 84 beats/min
ent elevation level decreased to normal during exercise, whereas a type 1 ECG is
Fig. 8. ST-segment variations associated with consuming a meal in a patient showing transient type 1 ST-segment elevation [36] with permission. Type 1 ST-segment
elevation appeared after breakfast and after dinner, returning to non-type 1 (saddleback type) at midnight and at 3:00 am in lead V2.
Fig. 7. ECG from an asymptomatic patient during glucose tolerance testing [30] with permission. Conﬁguration of the ST-segment in lead V2 60 min after glucose loading
shows typical coved-type ST-segment elevation.
M. Nishizaki et al. / Journal of Arrhythmia 29 (2013) 56–64 63respect to glucose-induced insulin level and increased vagal tone
after meals [35,36]. Moreover, augmentation and morphologic
changes in ST-segment elevation most prominently develop after
dinner. Therefore, recording at different times during daily life,
particularly after meals, is effective for detecting type 1 ECG
patterns.5. Clinical implications
In large cohort studies, the spontaneous appearance of a type
1 ECG pattern associated with symptoms of aborted sudden death
or unexplained syncope is indicative of a poor prognosis for
Brugada syndrome patients [7,8,12,54]. Moreover, the incidence
of cardiac events in symptomatic patients with only a drug-
induced type 1 ECG was 3–17% during the follow-up period
[8,13,14,48,54]. In contrast, there is a low incidence of arrhythmic
events in asymptomatic patients with either a spontaneous or
drug-induced type 1 ECG as compared to symptomatic subjects.
Speciﬁcally, asymptomatic patients with only a drug-induced
type 1 ECG have a very low incidence of cardiac events (0–1%)
[8,13,14,48,54]. Therefore, a drug-induced type 1 ECG in asymp-
tomatic patients does not appear to increase the arrhythmic risk.
Considering the infrequent appearance of a type 1 ECG pattern
in baseline recordings and its signiﬁcance for the detection ofarrhythmic events, the frequency and number of ECG recordings
used to judge whether individuals show a type 1 or non-type
1 ECG at baseline are quite important [54].
Consequently, in asymptomatic individuals, multiple and
repeated ECG recordings rather than drug testing are recom-
mended for detecting the transient appearance of a spontaneous
type 1 ECG, which may indicate the future development of
arrhythmic events. Moreover, in addition recording at higher lead
positions, other provocation tests such as exercise testing, glucose
tolerance testing, and full-stomach testing, which provoke similar
conditions to those of the spontaneous appearance of a type
1 ECG, may be useful in asymptomatic patients showing only a
non-type 1 ECG [30,32,53].Conﬂict of interest
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